Yes! These two PD-1 are included in the reimbursement scope

On May 21, Zhuhai branch of China Life Insurance Co., Ltd issued a "TongZhou on clarifying the drug catalogue (the third batch) of self funded cancer drugs under Zhuhai supplementary medical insurance" According to the notice, tereprizumab injection (tuoyi) of junshibio and pabolizumab injection (coreda) of mosadong are currently included in the reimbursement scope Among them, treprizumab injection is a new product From March 2, 2019, eligible insured can enjoy the treatment of cancer self funded drug project Its indication is suitable for the treatment of unresectable or metastatic melanoma which has failed to receive systemic treatment in the past But pabolizumab injection is the product of PD-1 mAb which has been included before In addition, the release documents show that the product has increased lung cancer indications within the scope of reimbursement Specifically, it is "the combination of pemetrexed and platinum chemotherapy is suitable for the first-line treatment of metastatic non squamous non-small cell lung cancer (NSCLC) with EGFR gene mutation negative and alk negative According to the public information, Zhuhai has released two batches of catalogues, including lenalidomide capsules It is worth noting that the two PD-1 are included in the reimbursement scope Strictly speaking, they are not medical insurance reimbursement, but supplementary medical insurance beyond medical insurance It originates from the "great love and boundless" additional supplementary medical insurance project announced by Zhuhai human resources and Social Security Bureau on December 13, 2018 It has been officially implemented since 2019, with an annual premium of 190 yuan per person The premium can be purchased with the individual account fund or cash of medical insurance From the perspective of treatment, it is divided into four parts: first, 90% of the total hospitalization approved medical expenses incurred by the insured within the year of social security are reimbursed, which are more than 600000 yuan and less than 1 million yuan The second is that the insured of malignant tumor will be reimbursed for 90% of the total amount of anti-tumor self expense drugs that meet the requirements, which are more than 10000 yuan and less than 300000 yuan; the newly diagnosed and recurrent malignant tumors in the insurance year can enjoy PET-CT inspection project compensation once, with the reimbursement rate of 60% The third is to reimburse 90% of the medical expenses of the inpatients that meet the requirements for personal burden of more than 30000 yuan and less than 300000 yuan Fourthly, the insured with 10 major diseases diagnosed for the first time will be given a cash subsidy of 20000 yuan Cheng Zhitao, deputy director of Zhuhai Municipal Bureau of human resources and social security, once said that the project is responsible for its own profits and losses and will not affect the safety of social security fund It can be seen that with the gradual adjustment of the medical insurance catalogue and the improvement of the supplementary medical insurance mechanism, more and more cancer drugs will be included in the reimbursement scope For enterprises, how to expand more indications with clinical value and how to quickly connect with various types of insurance is an urgent matter.